Volume 6.23 | May 30

Volume 6.23, May 30, 2005
     In this issue: Science | Policy | Business | NIH | CBER | Regulatory
Cell Therapy News on Facebook  Cell Therapy News on Twitter

Top Stories

Story: Double Triumph in Stem Cell Quest: Embryonic Stem Cells without Cloning

Story: Notch a Key Regulator of Hematopoietic Stem Cells


Stem Cell Hope for Liver Disease
Researchers have begun a pioneering trial using patients’ own stem cells to treat their chronic liver disease.

Team IDs Mechanism for Multiplying Adult Stem Cells
While research on human embryonic stem cells gets most of the press, scientists are also investigating the potential therapeutic uses of adult stem cells.

Protein Helps Regulate The Genes Of Embryonic Stem Cells
New research from University of North Carolina at Chapel Hill shows how a protein may be crucial to the regulation of genes in embryonic stem cells.

Liver Cells ‘Could Beat Diabetes’
Scientists have turned adult liver cells into insulin-producing cells able to treat diabetes when transplanted into mice.

Gene Therapy Promises the Holy Grail of Performance Enhancement
A new gene therapy technique, which is more than twice as effective as steroids at boosting muscle, will soon be given the go-ahead for testing on humans.

Enrolling Patients with Peripheral Arterial Disease (PAD) in Gene Therapy Study, Rush University Medical Center
“The goal of gene therapy is to stimulate the growth of new blood vessels. The additional blood vessels will carry more blood into the legs, alleviating pain and healing ulcers,” said Dr. Jeffrey Snell, study principal investigator and interventional cardiologist at Rush University Medical Center. 

Hwang Starts Gathering Stem Cell ‘Dream Team’
Hwang’s team is to be picked from top research centers in different areas such as stem cell safety, animal testing and clinical trials needed to advance the practical use of stem cell research.

Transplanting Kidneys Which Have Stones Poses Little Risk to Organ’s Viability
Results from a Mayo Clinic study suggest that using kidneys which have kidney stones for living donor transplant has little impact on the organ’s function one year later.


Clonogenic Cell Survival Assay

Epigenetic Regulation of Hematopoietic Stem Cell Self-renewal by Polycomb Group Genes

Recovery Capacity of Glial Progenitors After In Vivo Fission-neutron or X Irradiation: Age Dependence, Fractionation and Low-dose-rate Irradiations

Tumor Vaccine: Current Trends in Antigen Specific Immunotherapy


House Defies Bush, Approves Stem Cell Bill
In defiance of a presidential veto threat, senators who support embryonic stem cell research are pushing for a quick vote on a bill passed by the House that would lift funding restrictions on such studies.

Majority of U.S. Physicians Support Embryonic Stem Cell Research on Moral Grounds
A new national study conducted among 1,622 U.S. physicians reveals that the majority of physicians are receptive to the concept of embryonic stem cell research on moral grounds.



Stem Cell Firms Get Bill Activity Boost
Biotech companies that use stem cell technologies received a boost Friday after House Republican leaders said they would support a research bill that encouraged harvesting the cells from umbilical cords, in light of a presidential veto threat over a bill calling for the use of embryonic cells.

Cellerant in Race to Be First to Market Stem Cell Therapy
With a new $16 million round of venture capital money in its pocket and plans for more clinical trials by the end of the year, stem cell biotechnology company Cellerant Therapeutics Inc. hopes to get one of the first commercially viable stem cell therapies on the market, possibly in the next 18 months.

Cell Genesys Reports Positive Follow-Up Data From Trial of GVAX Vaccine
Cell Genesys has reported additional results from its second multicenter Phase II trial of GVAX vaccine for prostate cancer which evaluated escalating doses of the vaccine in 80 patients with advanced hormone-refractory metastatic prostate cancer.

Chromos and Targeted Molecules Corporation to Merge
Chromos Molecular Systems Inc., a cellular engineering and therapeutics company, announced today that it has agreed to acquire Targeted Molecules Corporation, a biotechnology company focused on the research and development of two antibody product candidates for treatment of multiple sclerosis and acute thrombosis.

CytoGenix Obtains HIV Vaccine License from NIH
CytoGenix, Inc. announced today that it has obtained a commercial evaluation license from the National Institutes of Health (NIH) for a DNA plasmid developed by scientists from the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC).

Dendreon Announces Results of Provenge Study in Early-Stage Prostate Cancer

Genitope Moves to Fremont
The biotechnology firm said Monday that it has signed 15-and-a-half year leases for its commercial manufacturing and new corporate headquarters in Ardenwood Technology Park in Fremont, owned by Peery-Arrillaga.

GenVec Gets OK to Resume Gene Therapy Trials
GenVec, Inc. announced today that the U.S. Food and Drug Administration (FDA) informed the company that it may resume its Phase II clinical trial of TNFerade(TM) in rectal cancer.

MultiCell Technologies Announces Licensing Agreement Between Bristol-Myers Squibb and MultiCell’s Licensee, Xenotech, LLC
MultiCell Technologies, Inc., a leading supplier of immortalized non-tumorigenic human hepatocytes as pharmaceutical candidate optimization tools announced today that its licensee, XenoTech, LLC, executed a three-year use and propagation agreement with pharmaceutical company Bristol-Myers Squibb.

ProCord Trial for Complete Spinal Cord Injury Now Live at Shepherd Center in Atlanta

TheraVitae And Chaophya Hospital Pave Way For Adult Stem Cell Therapy In Thailand


Malachite Management has joined forces with established and reputable authors and publishers to bring you the following market reports outlining the very latest in Cell Therapy, Gene Therapy, and Immunotherapeutic approaches to Cancer. 

“Cell Therapy – Technologies, Markets, and Companies” is over 400 pages of the basic technologies, clinical applications, market analysis, and company profiles related to the cell therapy industry worldwide.
For more information, including order forms, please see:

Cell Therapy Report Summary
Cell Therapy Sample Chapter
Cell Therapy Table of Contents Vol. 1  Vol. 2
Cell Therapy Order Form

“Gene Therapy – Technologies, Markets, and Companies” is over 500 pages of the basic technologies, clinical applications, market analysis, and company profiles related to the gene therapy industry worldwide.
For more information, including order forms, please see:

Gene Therapy Report Summary
Gene Therapy Table of Contents Vol. 1 Vol. 2
Gene Therapy Order Form

The Immunotherapy Reports cover the most recent developments in the immunotherapeutic approaches to cancer.

A Shift in Cancer Immunotherapy Strategies?
Immunotherapy Strategies Executive Summary
Immunotherapy Strategies Table of Contents

Future Perspectives in Cancer Immunotherapy
Future Perspectives Executive Summary
Future Perspectives Table of Contents

Immunotherapy Reports Order Form



NIH Guide for Grants and Contracts – Week Of May 27, 2005


All new CBER information can be reached from the What’s New page

Human Cells, Tissues, and Cellular and Tissue-Based Products; Donor Screening and Testing, and Related Labeling; Interim Final Rule





Draft Guidance for Industry on Antiviral Drug Development-Conducting Virology Studies and Submitting the Data to the Agency; Availability

For Country-Specific & International Regulatory Resources, Including Regulatory Agencies Such As the FDA, EMEA, & More, Please Visit The Regulatory Page On The Cell Therapy News Website 


This meeting has been added to the calendar this week:

5th International Meeting on Minimal Residual Cancer. San Francisco, California
September 11-14

To View an Up-to-Date List of Cell Therapy-Related Meetings, Please Visit The Meetings Page  On The Cell Therapy News Website


To View a List of Cell Therapy-Related Journals, Please Visit The Journals Page On The Cell Therapy News Website


For information on posting an opportunity email: [email protected]

Acting President
San Diego, California (California Institute of Regenerative Medicine)

Assistant Supervisor (Human Cellular Therapy) 
Rochester, Minnesota (Mayo Clinic)

Cell Processing Medical Technologists 
Oldsmar, Florida (Cryo-Cell International Inc.)

Cell Therapy Scientist 
Philadelphia, Pennsylvania (RheoGene, Inc.)

Cell Therapy Specialist 
Hackensack, New Jersey (Progenitor Cell Therapy, LLC)

Cell Therapy Supervisor 
New York, New York (New York Blood Center)

Cell Therapy Technologist 
New York, New York (New York Blood Center)

Cellular Production Lead Technician
Seattle, Washington (Fred Hutchinson Cancer Research Center)

Clinical Laboratory Scientist
Los Angeles, California (Cedars-Sinai Medical Center)

Clinical Consultant  
Deerfield, Illinois (Baxter Healthcare)

Consultant– (AABB)

Director of Cell Therapy
New York, New York (New York Blood Center)

Director of Research Programs 
Toronto, Ontario (Ontario Genomics Institute)

Faculty Positions 
Singapore (John Hopkins Singapore)

Instrumentation Engineer II 
Gaithersburg, Maryland (Maxcyte)
Interdisciplinary Scientist (Pharmacology/Toxicology) NEW!
Rockville, Maryland (CBER)

Laboratory Manager 
Hackensack, New Jersey (Progenitor Cell Therapy, LLC)

Laboratory Supervisor (Stem Cell Lab)
Charlottesville, Virginia (University of Virginia Health System)

Lead Assessor (Part Time) 
Bethseda, Maryland (AABB)

Manager, Device Engineering
Gaithersburg, Maryland (Maxcyte)

Manager, Quality Assurance 
Gaithersburg, Maryland (Maxcyte)

Marketing Manager 
Denver, Colorado (Gambro BCT)

Medical Laboratory Technologist (Stem Cell)
Roswell Park Cancer Institute (Buffalo, New York)

Post Doctoral Fellowship 
Memphis, Tennessee (St. Jude Children’s Research Hospital)

Program Leader: Cell Biology (Professor/Associate Professor) 
Melbourne, Australia (Peter MacCallum Cancer Centre)

Quality Assurance Associate
Hackensack, New Jersey (Progenitor Cell Therapy, LLC)

Quality Manager 
Sydney, Australia (Bone Marrow Transplant Network NSW)

Research Associate II 
Gaithersburg, Maryland (Maxcyte)

Senior Hospital Scientist 
Sydney, Australia (Australian Stem Cell Facility Sydney Children’s Hospital)

Senior Scientist 
Brussels, Belgium (Beta-Cell NV)

Scientific Director 
Boston, Massachusetts (CBR Insitute for Biomedical Research CHCT)

Scientific/Technical Officer,Stem Cell Transplant Laboratory/Haematology 
Sydney, Australia (SWAPS, Liverpool Hospital)

Scientist, Bacteriology
Potters Bar, Hertfordshire, England (National Institute for Biological Standards and Control)

Stem Cell Specialist
Philadelphia, PennsylvaniaA (Children’s Hospital of Philadelphia)

Stem Cell Techonologist 
Salt Lake City, Utah (University of Utah Hospital and Clinics Stem Cell Laboratory)

Supervising Medical Laboratory Technologist (Quality Assurance)
Buffalo, New York (Roswell Park Cancer Institute)

Supervising Medical Laboratory Technologist (HLA, Stem Cell, Therapeutic Apheresis) 
Buffalo, New York (Roswell Park Cancer Institute)

Supervisor Cellular Activities 
New York, New York (Memorial Sloan-Kettering Cancer Center)

Therapy Scientist
(Therapeutic Aphaeresis and Cell Therapy)
Denver, Colorado (Gambro BCT)


International Society for Cellular Therapy

Upcoming Meetings & Conferences:

2005 Cell Therapy Audioconference Series

5th Annual Somatic Cell Therapy Symposium. Bethesda, Maryland
Sept. 15-18, 2005

Profiled Journal



Cytotherapy now incorporates “Cytokines, Cellular & Molecular Theory”

Join ISCT ($130) and receive the journal as a benefit of membership

Current Volume: Volume 7, Number 2 / May 2005

Cytotherapy publishes original research, reviews, meeting reports, special focus issues and letters in the general field of cell therapy. The scope of the journal includes basic and applied research with hematopoietic and non-hematopoietic stem cells , immune cells, and antigen-presenting cells. Therapeutic topics within the scope of Cytotherapy include ex-vivo and in-vivo aspects of gene therapy, immunotherapy, stem cell transplantation and tissue regeneration. Cytotherapy particularly welcomes
contributions from researchers, clinicians, technicians and individuals involved in regulatory aspects of cell therapy.

 Learn more about Cell Therapy News:  Archives  |  Events  |  Update Profile  |  Contact Us